{"url_path":"/sec/bbot/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1869105/0001193125-26-219829-index.html","accession_number":"0001193125-26-219829","cik":"0001869105","ticker":"BBOT","issuer_name":"BridgeBio Oncology Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1869105/0001193125-26-219829-index.html","primary_entity_key":"0001869105","primary_entity_name":"BridgeBio Oncology Therapeutics, Inc."},"word_count":781,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\nExhibit\n\nNumber\n\n \n\nDescription\n\n2.1*†\n\n \n\n[Business Combination Agreement, by and among Helix Acquisition Corp. II, TheRas, Inc. and Helix II Merger Sub, Inc., dated as of February 28, 2025.](bbot-ex2_1.htm)\n\n2.2*\n\n \n\n[Amendment No. 1 to Business Combination Agreement, by and among Helix Acquisition Corp. II, TheRas, Inc. and Helix Merger Sub, Inc., dated as of June 17, 2025.](bbot-ex2_2.htm)\n\n3.1\n\n \n\n[BridgeBio Oncology Therapeutics, Inc. Certificate of Incorporation (incorporated by reference to Exhibit 3.1 the Registrant’s Current Report on Form 8-K filed on August 12, 2025).](https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/ea025066201ex3-1_bridge.htm)\n\n3.2\n\n \n\n[BridgeBio Oncology Therapeutics, Inc. Bylaws (incorporated by reference to Exhibit 3.2 the Registrant’s Current Report on Form 8-K filed on August 12, 2025)](https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/ea025066201ex3-2_bridge.htm).\n\n4.1\n\n \n\n[Specimen Common Stock Certificate of BridgeBio Oncology Therapeutics, Inc. (incorporated by reference to Exhibit 4.1 in the Registrant’s proxy statement/prospectus filed on July 9, 2025)](https://www.sec.gov/Archives/edgar/data/1869105/000121390025056321/ea023740105ex4-1_helix2.htm).\n\n10.1#*\n\n \n\n[Stevenson-Wydler (15 USC 3710a) Cooperative Research and Development Agreement, dated May 22, 2018, by and between Lawrence Livermore National Security, LLC (the “LLNS”) and BBOT, as amended by Amendment No. 1 dated December 2, 2019, as further amended by Amendment No. 2 dated May 21, 2021, as further amended by Amendment No. 3 dated as of June 22, 2022, as further amended by Amendment No. 4 dated as of December 21, 2023, as further amended by Amendment No. 5, dated as of May 20, 2025, as further amended by Amendment No. 6 dated as of February 5, 2026.](bbot-ex10_1.htm)\n\n10.2#*\n\n \n\n[Cooperative Research and Development Agreement, dated March 3, 2017, between Frederick National Laboratory for Cancer Research (FNLCR) Operated by Leidos Biomedical Research, Inc. and the Registrant, as amended by Amendment No. 1 dated January 19, 2018, as further amended by Amendment No. 2 dated January 2, 2019, as further amended by Amendment No. 3 dated November 14, 2019, as further amended by Amendment No. 4 dated January 13, 2020, as further amended by Amendment No. 5 dated September 22, 2021, as further amended by Amendment No. 6 dated March 27, 2023, as further amended by Amendment No. 7 dated August 20, 2024, as further amended by Amendment No. 8 dated September 2, 2025, as further amended by Amendment No. 9 dated December 3, 2025.](bbot-ex10_2.htm)\n\n10.3*\n\n \n\n[Amendment No. 8 to Transition Services Agreement, by and among TheRas, Inc., BridgeBio Services, Inc., BridgeBio Oncology Therapeutics, Inc. and BridgeBio Pharma LLC as of April 29, 2026.](bbot-ex10_3.htm)\n\n14.1\n\n \n\n[Code of Business Conduct and Ethics (incorporated by reference to Exhibit 14.1 the Registrant’s Current Report on Form 8-K filed on August 12, 2025).](https://www.sec.gov/Archives/edgar/data/1869105/000121390025075190/ea025066201ex14-1_bridge.htm)\n\n19.1*\n\n \n\n[Insider Trading Policy](bbot-ex19_1.htm).\n\n31.1*\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](bbot-ex31_1.htm)\n\n31.2*\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](bbot-ex31_2.htm)\n\n32.1+\n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](bbot-ex32_1.htm)\n\n32.2+\n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](bbot-ex32_2.htm)\n\n101.INS\n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101)\n\n \n\n* Filed herewith.\n\n† Certain schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the Commission upon request.\n\n# Portions of this exhibit have been omitted because they are both (i) not material and (ii) the type of information that the registrant treats as private or confidential.\n\n+ This certification will not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.\n\n99\n\n[Table of Contents](#toc_page)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nBRIDGEBIO ONCOLOGY THERAPEUTICS, INC.\n\nDate: May 12, 2026\n\nBy:\n\n/s/ Pedro J. Beltran\n\nPedro J. Beltran, Ph.D.\n\nChief Executive Officer\n\n \n\nDate: May 12, 2026\n\nBy:\n\n/s/ Idan Elmelech\n\n \n\n \n\n \n\nIdan Elmelech\n\n \n\n \n\n \n\nChief Operating and Principal Financial Officer\n\n \n\n100"}